1-5 of 5
Jason A. Dubovsky, PhD
Close
Sort by
Journal Articles

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Jason A. Dubovsky, PhD, Julie Rytlewski, PhD, Lin Yang, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 503.
https://doi.org/10.1182/blood-2019-127603
Published: 2019
Journal Articles

Multiplexed Immunofluorescence (IF) Analysis and Gene Expression Profiling of Biopsies from Patients with Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL) Treated with Lisocabtagene Maraleucel (liso-cel) in Transcend NHL 001 Reveal Patterns of Immune Infiltration Associated with Durable Response

David J. Reiss, PhD, Trevor Do, David Kuo, Vanessa E. Gray, N. Eric Olson, Chung-Wein Lee, Mary H. Young, PhD, Shradha Srinivasan, Falon D. Gray, DVM, DACVP, Brian Fox, Suzana Couto, Jason A. Dubovsky, PhD, Frank Schmitz, Kathryn Newhall
Journal: Blood
Blood (2019) 134 (Supplement_1): 202.
https://doi.org/10.1182/blood-2019-127683
Published: 2019
Journal Articles

Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, William G. Wierda, MD PhD, Jason A. Dubovsky, PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Alan Mitchell, MSc, Jerill Thorpe, BSc, Lin Yang, PhD, Kathleen A. Dorritie, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 300.
https://doi.org/10.1182/blood-2018-99-110462
Published: 2018
Journal Articles

Pharmacologic Inhibition with Duvelisib (IPI-145) and Genetic Inhibition of PI3K p110δ Antagonizes Intrinsic and Extrinsic Survival Signals in Chronic Lymphocytic Leukemia (CLL)

Shuai Dong, MS, Daphne Guinn, Jason A Dubovsky, PhD, Yiming Zhong, PhD, Amy Lehman, Jeff Kutok, MD, PhD, Jennifer A. Woyach, MD, John C. Byrd, MD, Amy J. Johnson, PhD
Journal: Blood
Blood (2014) 124 (21): 3324.
https://doi.org/10.1182/blood.V124.21.3324.3324
Published: 2014
Journal Articles

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694

Yiming Zhong, PhD, Shuai Dong, MS, Kelsey Thornton, Anjali Mishra, PhD, Pierluigi Porcu, MD, Michael Bradshaw, Angelina Bisconte, Timothy Owens, Erik Verner, Ken Brameld, Jens Oliver Funk, MD, Ronald Hill, Amy J. Johnson, PhD, Jason A Dubovsky, PhD
Journal: Blood
Blood (2014) 124 (21): 272.
https://doi.org/10.1182/blood.V124.21.272.272
Published: 2014